PCSK9 as a therapeutic target in atherosclerosis

Current Atherosclerosis Reports

Volumn 12, Issue 3, 2010, Pages 151-154

  Marian, Ali J ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MEVINOLIN; MONOCLONAL ANTIBODY; PCSK9 MONOCLONAL ANTIBODY 1; UNCLASSIFIED DRUG;

ANIMAL CELL CULTURE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; IN VITRO STUDY; NONHUMAN; NOTE; PRIMATE; PROTEIN EXPRESSION; SINGLE DRUG DOSE;

EID: 77953535433     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-010-0099-2     Document Type: Note

References (12)

1. Lagace TA, Curtis DE, Garuti R, et al.: Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest 2006, 116:2995-3005.
2. Abifadel M, Varret M, Rabes JP, et al.: Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 2003, 34:154-156.
3. Cohen J, Pertsemlidis A, Kotowski IK, et al.: Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat Genet 2005, 37:161-165.
4. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006, 354:1264-1272.
5. Chen SN, Ballantyne CM, Gotto AM Jr, et al.: A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis. J Am Coll Cardiol 2005, 45:1611-1619.
6. Frank-Kamenetsky M, Grefhorst A, Anderson NN, et al.: Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci U S A 2008, 105:11915-11920.
7. Ridker PM, Danielson E, Fonseca FA, et al.: Reduction in Creactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009, 373:1175-1182.
8. Dubuc G, Chamberland A, Wassef H, et al.: Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia. Arterioscler Thromb Vasc Biol 2004, 24:1454-1459.
9. Marian AJ: Nature's genetic gradients and the clinical phenotype. Circ Cardiovasc Genet 2009, 2:537-539.
10. Zhao Z, Tuakli-Wosornu Y, Lagace TA, et al.: Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote. Am J Hum Genet 2006, 79:514-523.
11. Graham MJ, Lemonidis KM, Whipple CP, et al.: Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 2007, 48:763-767.
12. Duff CJ, Scott MJ, Kirby IT, et al.: Antibody-mediated disruption of the interaction between PCSK9 and the lowdensity lipoprotein receptor. Biochem J 2009, 419:577-584.